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Opioid prescribing trends have been investigated in many countries. However, the 34 
patterns of over-the-counter purchases of opioids without a prescription, such as 35 
codeine combinations, are mostly unknown. 36 
 37 
Objective 38 
We aimed to assess national sales and expenditure of over-the-counter codeine-39 
containing products purchased in 31 countries over six years. 40 
 41 
Methods 42 
We conducted a retrospective observational study using electronic point-of-sales data 43 
from the human data science company, IQVIA, for Argentina, Belgium, Brazil, 44 
Bulgaria, Canada, Croatia, Estonia, Finland, France, Germany, Greece, Ireland, Italy, 45 
Japan, Latvia, Lithuania, Mexico, The Netherlands, Poland, Portugal, Romania, Russia, 46 
Serbia, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, the UK, and the 47 
USA. We calculated annual mean sales (units per 1000 of the population) and public 48 
expenditure (GBP, £ per 1000) for each country between April 2013 and March 2019. 49 
We quantified changes over time and the types of products sold. 50 
 51 
Results 52 
31.5 billion units of codeine, costing £2.55 billion, were sold over-the-counter in 31 53 
countries between April 2013 and March 2019. Total sales increased by 3% (3025 54 
units/1000 in 2013 to 3111 in 2019) and public expenditure doubled (£196/1000 in 55 
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2013 to £301/1000 in 2019). Sales were not equally distributed; South Africa sold the 56 
most (31 units/person), followed by Ireland (24 units/person), France (16 units/person), 57 
Latvia (15 units/person), and the UK (11 units/person). The types of products (n=569) 58 
and formulations (n=12) sold varied. 59 
 60 
Conclusion and Relevance 61 
In many parts of the world, substantial numbers of people may be purchasing and 62 
consuming codeine from over-the-counter products. Clinicians should ask patients 63 
about their use of over-the-counter products and public health measures are required to 64 
improve the collection of sales data and safety of such products. 65 
 66 
Study protocol pre-registration: https://osf.io/ay4mc 67 
 68 
Key points 69 
• Total sales and public expenditure of over-the-counter products containing 70 
codeine increased from April 2013 to March 2019 in line with increased trends 71 
of global opioid use. 72 
• There was substantial variation in mean sales of over-the-counter codeine 73 
between countries. 74 
• In countries with access to over-the-counter codeine, these sales data should be 75 
reviewed to informed regulatory decisions and requirements for public health 76 
measures to ensure safety. 77 
 78 
79 
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1 Introduction 80 
Prescribing patterns of opioids are documented in many countries [1–7]. However, 81 
opioids such as analgesic combinations containing codeine can be purchased over-the-82 
counter (OTC) without a prescription or consultation with a doctor or prescriber in most 83 
countries. As access to granular data on OTC sales has been limited, previous research 84 
on the use of non-prescribed codeine has relied on case reports [8–10], self-reported 85 
questionnaires [11–18], qualitative studies [19–22], and data from poisons centres, 86 
hospital admissions, or coronial systems [23–27]. It is therefore unknown whether OTC 87 
sales of codeine have followed trends similar to the use of prescribed opioids. 88 
 89 
Codeine (3-methylmorphine) is used for its analgesic, antidiarrheal, and antitussive 90 
effects [28–30]. It is often combined with other analgesics, such as paracetamol, and 91 
non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. These 92 
combinations have greater efficacy than codeine alone [28,31,32]. But most clinical 93 
trials testing the efficacy of codeine have used high doses (25–90 mg), which are not 94 
available OTC [31–33]. A Cochrane overview of systematic reviews on oral OTC 95 
analgesics for acute pain found no studies or data that could be extracted on 96 
combinations of analgesics containing low doses of codeine [33]. A systematic review 97 
of the efficacy and safety of low-dose (≤30 mg) codeine included ten RCTs [34]. It 98 
reported low- to moderate-quality evidence that combination products of low-dose 99 
codeine provided little to moderate pain relief for acute and chronic pain conditions in 100 
the short term [34]. In observational studies products containing codeine have been 101 
associated with dependence, misuse, death, and collateral toxicity from combinations 102 
with paracetamol and ibuprofen [9,25]. 103 
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Access to codeine without a prescription can bolster the perception of safety, and in 105 
some settings abuse of OTC codeine is normalised and encouraged. Mixing codeine 106 
cough syrup with alcohol and or soft drinks has been popularised in rap music and by 107 
American athletes, who make a drink called "purple drank" from codeine syrup and 108 
soda [35]. OTC codeine has been used to manufacture illicit morphine and heroin and to 109 
create a cheap heroin substitute called "krokodil" [36,37]. The use of "Krok" has been 110 
reported in Russia, Europe, the UK, and North America, and its adverse effects from 111 
intravenous use include damage to blood vessels, skin, muscles, and bones, multiorgan 112 
failure, and death [36,38]. Thus, the growing opioid problem is incomplete without 113 
evaluation of OTC sales of codeine. 114 
 115 
Regulation of codeine-containing products varies across the world, making it difficult to 116 
estimate how much they are used [39]. Under the 1961 Single Convention on Narcotic 117 
Drugs, codeine is a Schedule III drug [40]. Drugs in this Schedule reportedly "are not 118 
liable to abuse and cannot produce ill effects", and thus it is not mandatory to report 119 
data on their consumption to the International Narcotics Control Board (INCB). In a 120 
report presented at the WHO's Expert Committee on Drug Dependence in October 121 
2019, reviewing codeine formulations listed in Schedule III, the INCB reported a 64% 122 
increase in demand for codeine in the last decade [39]. 123 
 124 
However, governments can also mandate regulation of codeine. Minnesota (July 2013), 125 
Manitoba (February 2016), France (July 2017), and Australia (February 2018) have 126 
reclassified codeine to prescription-only [41–44]. A review of OTC codeine regulations 127 
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in the European Union showed that more than half of member countries did not permit 128 
OTC sale of codeine as of March–August 2014 [45]. Despite variation in codeine's 129 
regulatory status, studies have analysed consumption of OTC cough syrup containing 130 
codeine in Taiwan [46] and the impact of rescheduling codeine to prescription-only in 131 
Australia [47,48]. We aimed to assess national sales and public expenditure on OTC 132 
codeine-containing products purchased in countries with available data. 133 
 134 
2 Methods 135 
2.1 Design and data source 136 
We conducted a retrospective observational study using consumer health sales data 137 
from IQVIA [49], which has previously been used in observational research on a range 138 
of medications [46–48,50–53]. The data included products containing codeine in the 139 
adult pain relief category, which were collected using scan track barcodes from 140 
electronic point-of-sale (EPoS) store data in all countries that provided data, including 141 
Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia, Estonia, Finland, France, 142 
Germany, Greece, Ireland, Italy, Japan, Latvia, Lithuania, Mexico, The Netherlands, 143 
Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, Spain, 144 
Switzerland, Thailand, the UK, and the USA. IQVIA extracted the data on 16 September 145 
2019 and provided quarterly sales from 1 April 2013 to 31 March 2019. IQVIA's sample 146 
of data is based on audits and covers a median of 73% (IQR: 58–86%) of 147 
pharmaceutical markets (Table S1 in Supplement 1). Annual population statistics in 148 
calendar years (2013 to 2018) were sourced from the World Bank [54]. 149 
 150 
2.2 Data analysis 151 
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We extracted details from the pack information and used descriptive statistics to 152 
determine the numbers and types of products sold across the 31 countries. Data on 153 
dosages were missing from the pack information for most countries, so we used 154 
IQVIA’s standard units to account for liquid and solid dosage forms. We calculated the 155 
total units sold over the study period and the totals for each year (e.g. from quarter two 156 
in 2013 to quarter one in 2014). We also calculated the mean number of units sold over 157 
six years, adjusted for population. We created an annual rate of units sold per 1000 of 158 
each year's population for each country to examine trends over time. 159 
 160 
For expenditure, IQVIA converted sales to pounds sterling (GBP, £) for each country on 161 
the date of data extraction (16 September 2019). We calculated annual totals, mean 162 
public expenditure for each country, adjusted for population, and a rate of GBP per 163 
1000 to assess changes over time. 164 
 165 
2.3 Software and data sharing 166 
We used Stata v16 and Python v3 in Jupyter Notebooks with pandas [55], seaborn [56], 167 
and matplotlib [57] libraries for analysis and figures. The commercial information we 168 
used requires a fee to access. Thus, we cannot openly share the data, owing to 169 
contractual agreements with IQVIA. However, we have openly shared our statistical 170 
code at GitHub [58], preregistered [59] and published [60] our study protocol, and 171 
shared all our study materials via the Open Science Framework (OSF) [61]. 172 
 173 
3 Results 174 
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31.5 billion units containing codeine were sold across 31 countries over the study period 175 
(April 2013 to March 2019). Total sales increased by 2.8%, from 3025 units/1000 in 176 
2013–14 to 3111 units/1000 in 2018–19. However, the distribution of sales between 177 
countries was not uniform. Five countries represented 90% of all OTC codeine sales. 178 
South Africa accounted for the greatest volume of sales (34%), followed by France 179 
(20%), Japan (16.5%), the UK (14.5%), and Poland (5%). South Africa sold the most 180 
(mean of 31 units/person, see Figure 1), followed by Ireland (24 units/person), France 181 
(16 units/person), Latvia (15 units/person), and the UK (12 units/person). 182 
 183 
[Figure 1 near here] 184 
 185 
In the most recent year (April 2018–March 2019), South Africa sold the most (38 186 
units/person), followed by Ireland (23 units/person), Latvia (16 units/person), the UK 187 
(11 units/person), and Japan (10.7 units/person) (Table S2 in Supplement 1). 188 
 189 
Over time, 48% of countries (15/31) had increased OTC codeine sales. For countries in 190 
the top quartile of sales (Figure 2A), trends increased in South Africa (30%), Ireland 191 
(8%), Latvia (11%), and Poland (19%), and sales fell in France (99%), the UK (7%), 192 
Serbia (4%), and Croatia (17%).  For countries in the second-largest quartile of sales 193 
(Figure 2B), trends increased in Japan (1219%), Estonia (65%), Romania (10%), and 194 
Bulgaria (18%), and sales fell in Switzerland (50%), Finland (22%), The Netherlands 195 
(16%), and Slovenia (16%). Trends for countries in the bottom two quartiles are in 196 
Figure S1 and S2 in Supplement 1. 197 
 198 
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[Figure 2 (Figure 2A and Figure 2B) near here] 199 
 200 
The public spent £2.55 billion on OTC codeine-containing products in 31 countries over 201 
six years; expenditure increased by 54%, from £196/1000 in 2013–14 to £301/1000 in 202 
2018–19. Ireland had the largest mean public expenditure of £5.70 per person, followed 203 
by the UK (mean of £1.60/person), South Africa (£1.26/person), Croatia (£1.25/person), 204 
and Estonia (£1/person) (Figure 3). In April 2018 to March 2019, Ireland continued to 205 
have the largest public expenditure (£6.60/person), followed by South Africa 206 
(£1.64/person), the UK (£1.64/person), Japan (£1.47/person), and Estonia (£1.41) 207 
(Table S2 in Supplement 1). 208 
 209 
[Figure 3 near here] 210 
 211 
Most countries (58%, 18/31) had increased public expenditure over time. There were 212 
simultaneous increases (45%, 14/31) and decreases (39%, 12/31) in both sales and 213 
expenditure in most countries, while other countries (16%, 5/31) had a discordance in 214 
the direction of their sales and expenditure (Figure 4). 215 
 216 
[Figure 4 near here] 217 
 218 
There were 569 products and 12 formulations sold across 31 countries. Tablets were the 219 
most common formulations sold, followed by syrups, soluble tablets, and coated tablets 220 
(Figure S3 in Supplement 1). Products contained a median of three substances per 221 
combination (IQR: 2–4, range: 1–16). Limited details were available in the pack 222 
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information: the dosages of codeine were available in 17% of products (98 of 569) in 15 223 
countries. 224 
 225 
4 Discussion 226 
Many people are purchasing non-prescribed codeine in several parts of the world. Total 227 
sales and public expenditure of OTC codeine products increased over time in line with 228 
previous trends of global opioid use. However, sales were not equally distributed across 229 
the 31 countries. 230 
 231 
According to IQVIA’s data, South Africa consistently sold the greatest volume of OTC 232 
codeine each year. In a study of opioid dependence in South Africa 5–8% of people in 233 
addiction treatment facilities reported problems with OTC codeine medications and 234 
cough mixtures as their primary or secondary drug of choice [62]. The availability of 235 
non-prescribed codeine may also have ramifications for neighbouring countries that 236 
restrict access. For example, there were reports in Zimbabwe that codeine-containing 237 
cough syrup was being illegally smuggled in from South Africa and sold on the streets 238 
after being outlawed in 2015 [63]. However, there are limited data in many countries on 239 
the prevalence of such activities and the extent of codeine use and misuse. 240 
 241 
Abuse of OTC codeine products has been encouraged and normalised on social media 242 
and in hip-hop music [64–66], which is a growing public health concern. A scoping 243 
review of the non-medical use of pharmaceuticals identified several ways in which 244 
codeine was reportedly being abused, including mixtures with alcohol or soft drinks 245 
(e.g. "purple drank") and in the production of home-made opiates (e.g. "krokodil") [67]. 246 
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Public health interventions are needed to prevent abuse, misuse, and pharmacy shopping 247 
of OTC codeine products, particularly in young adults. The hip-hop song titled "1-800-248 
273-8255", from the US suicide prevention lifeline, significantly increased public 249 
awareness of and calls to the hotline [68]. Thus, hip-hop music can also be used as a 250 
tool to tailor public health messages to young adults and counteract the glamourisation 251 
of codeine misuse. 252 
 253 
The growing recognition of codeine abuse and misuse has led governments in 254 
Minnesota, Manitoba, France, and Australia to reclassify codeine to prescription-only 255 
[41–44]. In South Africa, Canada, Switzerland, Ireland, and the UK, governments are 256 
proposing or considering plans to reclassify codeine-containing products to 257 
prescription-only [69–72]. Studies assessing the effect of rescheduling codeine to 258 
prescription-only in Australia showed a reduction in all codeine-related poisonings and 259 
no change in calls to poisons centres or sales of high-strength (>15 mg) prescribed 260 
codeine after reclassification [47,73]. The success of Australia’s rescheduling questions 261 
whether governments worldwide should make codeine prescription-only. But since 262 
many low- and middle-income countries experience barriers to accessing opioids [74–263 
76], the WHO recommends that codeine should not be upscheduled and for codeine to 264 
be included in essential medicines lists [77]. If a consensus on the status of OTC 265 
codeine products cannot be reached, data should be collected globally to monitor its use 266 
and harms. 267 
 268 
Changes to regulations of OTC codeine and differences in trade exemptions and 269 
disclosures of commercial interests at the country level may explain some of the 270 
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variation in sales [39]. For example, in France, sales fell considerably after codeine 271 
became prescription-only. In countries such as Canada, Germany, and the USA, which 272 
had high rates of prescribed opioids [76], mean sales of OTC codeine products were 273 
lower than countries without similar access to prescribed opioids. However, our figures 274 
depended on coverage of data from IQVIA during this time. Thus, it is hard to determine 275 
whether the variation in sales represents real differences between countries. 276 
 277 
Strengths and limitations 278 
We used IQVIA's standard units to measure sales, which allows liquid and solid dosage 279 
forms to be combined. The figures represent population-level sales and expenditure of 280 
OTC codeine in 31 countries, providing the best available proxy for actual use. Sales 281 
represented adult pain relief, although we calculated rates using population statistics for 282 
all age groups, including children. Codeine-containing products may also be purchased 283 
in large quantities from online pharmacies or the black market [78], not captured in 284 
these data. IQVIA’s coverage and the completeness of data may have also affected sales 285 
trends; they provided percentages on data coverage and converted expenditure to GBP 286 
at single time points, which may not accurately represent changes to such metrics over 287 
time. 288 
 289 
Better access to OTC sales data is required. Amendments to medicines legislation in the 290 
UK show how such data could be collected. The Misuse of Drugs Regulation 2001, the 291 
Medicines for Human Use (Administration and Sale or Supply) (Miscellaneous 292 
Amendments) Order 2007, and the Medicines (Sale or Supply) (Miscellaneous 293 
Provisions Amendment Regulations 2007) were updated to require pharmacies to 294 
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submit counts of private prescriptions for Schedule 2 and Schedule 3 controlled drugs to 295 
the National Health Service (NHS) Prescription Services for analysis, audit, and 296 
monitoring [79,80]. A similar system could be enforced through a public health 297 
organisation such as the WHO or the International Narcotics Control Board (INCB), 298 
which already collects governments’ annual drug statistics on opioids [81]. Such data 299 
could then be used by governments and researchers to monitor sales of OTC codeine 300 
and measure the impact of regulatory changes. 301 
 302 
Conclusions 303 
Codeine is one of the most widely accessible and used opioids worldwide. However, 304 
monitoring its use and preventing its misuse as an OTC product is a public health 305 
challenge. Healthcare professionals should ask their patients about their use of OTC 306 
products. Public health measures are needed to identify and prevent codeine misuse and 307 
increase awareness and education of the harms of codeine, particularly in young adults. 308 
Governments should review policies to improve the collection of sales data and safety 309 
of products sold OTC containing codeine. 310 
 311 
 312 
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Figure 1: Mean sales of over-the-counter (OTC) codeine-containing units sold over six 378 
years in 31 countries with data in descending order 379 
  380 
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Figure 2: Sales of over-the-counter (OTC) products containing codeine per 1000 of the 382 
population starting in April 2013 to March 2014, and ending in April 2018 to March 383 
2019, for countries in the top quartile (A) and second quartile (B) of sales 384 
385 
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Figure 3: Public expenditure on over-the-counter (OTC) codeine-containing units sold 387 
over six years in 31 countries with data in descending order 388 
  389 
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Figure 4: Percentage changes in sales (units sold per 1000 of the population) and public 392 
expenditure (£ per 1000) on products containing codeine sold over-the-counter (OTC) 393 
in 31 countries between April 2013 and March 2019 394 
  395 
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